| MeSH term | MeSH ID | Detail |
|---|---|---|
| Biliary Tract Neoplasms | D001661 | 7 associated lipids |
| Blepharitis | D001762 | 4 associated lipids |
| Blindness | D001766 | 6 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Bone Diseases | D001847 | 4 associated lipids |
| Bradycardia | D001919 | 13 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Brain Edema | D001929 | 20 associated lipids |
| Bronchiolitis | D001988 | 6 associated lipids |
| Bronchiolitis Obliterans | D001989 | 8 associated lipids |
| Burkitt Lymphoma | D002051 | 15 associated lipids |
| Burns | D002056 | 34 associated lipids |
| Candidiasis, Oral | D002180 | 11 associated lipids |
| Candidiasis, Vulvovaginal | D002181 | 8 associated lipids |
| Carcinoma, Squamous Cell | D002294 | 14 associated lipids |
| Cardiomyopathy, Hypertrophic | D002312 | 6 associated lipids |
| Cardiomyopathy, Restrictive | D002313 | 1 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
| Carpal Tunnel Syndrome | D002349 | 3 associated lipids |
| Catalepsy | D002375 | 30 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Gudas VM et al. | Comparison of the immunosuppressive and toxic effects of FK506 and cyclosporine in xenograft recipients. | 1989 | Transplant. Proc. | pmid:2468211 |
| Sato K et al. | Pancreaticoduodenal allotransplantation with cyclosporine and FK506. | 1989 | Transplant. Proc. | pmid:2468212 |
| Watanabe K et al. | Prolongation effect of a small dose of FK506, cyclosporine, or azathioprine on renal allografts in dogs treated with fractionated lymphoid irradiation and donor bone marrow cell infusion. | 1989 | Transplant. Proc. | pmid:2468213 |
| Sakamoto K et al. | Analysis of long-term acceptance of xenografts in rats induced by short-term administration of FK506. | 1989 | Transplant. Proc. | pmid:2468222 |
| Nakajima K et al. | Effects of 15-deoxyspergualin and FK506 on the histology and survival of hamster-to-rat cardiac xenotransplantation. | 1989 | Transplant. Proc. | pmid:2468223 |
| Ochiai T et al. | Comparative studies on the immunosuppressive activity of FK506, 15-deoxyspergualin, and cyclosporine. | 1989 | Transplant. Proc. | pmid:2468228 |
| Yasunami Y et al. | Effects of a novel immunosuppressive agent, FK-506, on islet allograft survival in the rat. | 1989 | Transplant. Proc. | pmid:2468234 |
| Kobayashi C et al. | Suppression of corneal graft rejection in rabbits by a new immunosuppressive agent, FK-506. | 1989 | Transplant. Proc. | pmid:2468254 |
| Kuroki H et al. | Experimental studies of vascularized allogeneic limb transplantation in the rat using a new immunosuppressive agent, FK-506: morphological and immunological analysis. | 1989 | Transplant. Proc. | pmid:2468255 |
| Kay JE et al. | The mechanism of action of the immunosuppressive drug FK-506. | 1989 | Cell. Immunol. | pmid:2478301 |
| Starzl TE et al. | FK 506 for liver, kidney, and pancreas transplantation. | 1989 | Lancet | pmid:2478846 |
| Arai K et al. | Limb allografts in rats immunosuppressed with FK506. I. Reversal of rejection and indefinite survival. | 1989 | Transplantation | pmid:2479130 |
| Francavilla A et al. | Augmentation of rat liver regeneration by FK 506 compared with cyclosporin. | 1989 | Lancet | pmid:2479802 |
| Walliser P et al. | Inhibition of murine B-lymphocyte proliferation by the novel immunosuppressive drug FK-506. | 1989 | Immunology | pmid:2480331 |
| Aoki M et al. | [Histological observations of immunosuppressive effects of FK-506 in canine lung allotransplantation]. | 1989 | Bull Chest Dis Res Inst Kyoto Univ | pmid:2482787 |
| Kay JE and Benzie CR | T lymphocyte activation through the C28 pathway is insensitive to inhibition by the immunosuppressive drug FK-506. | 1989 | Immunol. Lett. | pmid:2483716 |
| McCauley J et al. | Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. | 1989 Dec 23-30 | Lancet | pmid:2481200 |
| Collier SJ | Immunosuppressive drugs. | 1989-1990 | Curr. Opin. Immunol. | pmid:2484794 |
| Brown Z and Neild GH | FK-506 and haemolytic uraemic syndrome. | 1990 | Lancet | pmid:1689442 |
| Thomas J et al. | The immunosuppressive action of FK506. In vitro induction of allogeneic unresponsiveness in human CTL precursors. | 1990 | Transplantation | pmid:1689518 |
| Vathsala A et al. | Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. | 1990 | Transplantation | pmid:1689520 |
| Yamamoto K et al. | Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK506. | 1990 | Immunology | pmid:1689694 |
| Thomson AW | Interspecies comparison of the immunosuppressive efficacy and safety of FK 506. | 1990 | Transplant. Proc. | pmid:1689883 |
| Zeevi A et al. | Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. | 1990 | Transplant. Proc. | pmid:1689884 |
| Morris RE et al. | Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. | 1990 | Transplant. Proc. | pmid:1689885 |
| Todo S et al. | Early trials with FK 506 as primary treatment in liver transplantation. | 1990 | Transplant. Proc. | pmid:1689886 |
| Francavilla A et al. | FK 506 as a growth control factor. | 1990 | Transplant. Proc. | pmid:1689912 |
| Mazzaferro V et al. | Studies of the hepatotrophic qualities of FK 506 and CyA. | 1990 | Transplant. Proc. | pmid:1689913 |
| Kay JE et al. | The mechanism of action of FK 506. | 1990 | Transplant. Proc. | pmid:1689914 |
| Suzuki N et al. | Effects of a novel immunosuppressive agent, FK506, on human B cell activation. | 1990 | Clin. Exp. Immunol. | pmid:1690097 |
| McCauley J et al. | FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. | 1990 | Lancet | pmid:1690326 |
| Hoffman AL et al. | The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. | 1990 | Transplantation | pmid:1690469 |
| Woo J et al. | The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis. | 1990 | Scand. J. Immunol. | pmid:1690915 |
| Yasunami Y et al. | FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. | 1990 | Transplantation | pmid:1691535 |
| Propper DJ et al. | Low-dose FK 506 inhibits sensitisation after blood transfusions. | 1990 | Transplant. Proc. | pmid:1697114 |
| Tiebosch A et al. | Side effects of FK 506 in cynomolgus monkeys: a histopathologic study. | 1990 | Transplant. Proc. | pmid:1697115 |
| Dammeijer PF et al. | Combined effect of low-dose FK 506 and cyclosporine A on skin graft survival. | 1990 | Transplant. Proc. | pmid:1697116 |
| Imai K et al. | Pancreaticoduodenal allotransplantation with the use of FK 506, cyclosporine, and triple-regimen immunosuppression. | 1990 | Transplant. Proc. | pmid:1697117 |
| Iga C et al. | Prolonged survival of small intestinal allograft in the rat with cyclosporine A, FK 506, and 15-deoxyspergualin. | 1990 | Transplant. Proc. | pmid:1697118 |
| Deguchi K et al. | [Effects of novel immunosuppressant FK 506 in acute experimental allergic encephalomyelitis]. | 1990 | No To Shinkei | pmid:1697182 |
| Murase N et al. | Prevention of spontaneous diabetes in BB rats with FK 506. | 1990 | Lancet | pmid:1697397 |
| Justice RM et al. | The detection of proline isomerase activity in FK506-binding protein by two-dimensional 1H NMR exchange spectroscopy. | 1990 | Biochem. Biophys. Res. Commun. | pmid:1697463 |
| Todo S et al. | Liver, kidney, and thoracic organ transplantation under FK 506. | 1990 | Ann. Surg. | pmid:1697743 |
| Lee KK et al. | Comparison of short-term immunosuppressive therapy with cyclosporine and FK 506 in small-bowel transplantation. | 1990 | Transplant. Proc. | pmid:1702239 |
| Takai K et al. | Effects of FK506 on rat thymus: time-course analysis by immunoperoxidase technique and flow cytofluorometry. | 1990 | Clin. Exp. Immunol. | pmid:1702372 |
| Okubo Y et al. | FK506, a novel immunosuppressive agent, induces antigen-specific immunotolerance in active Heymann's nephritis and in the autologous phase of Masugi nephritis. | 1990 | Clin. Exp. Immunol. | pmid:1702373 |
| Arita C et al. | Inhibition by FK506 of established lesions of collagen-induced arthritis in rats. | 1990 | Clin. Exp. Immunol. | pmid:1702374 |
| Woo J et al. | Influence of FK506 and cyclosporin A on alloantibody production and lymphocyte activation following blood transfusion. | 1990 | Clin. Exp. Immunol. | pmid:1702375 |
| Mattila PS et al. | The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. | 1990 | EMBO J. | pmid:1702384 |
| Kawashima H et al. | Antigen-specific suppressor cells induced by FK506 in experimental autoimmune uveoretinitis in the rat. | 1990 | Invest. Ophthalmol. Vis. Sci. | pmid:1702408 |